Skip to main content

Table 6 Characteristics of patients with or without subsequent chemotherapy after treatment of nivolumab

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Variables All patients (n = 55) Subsequent chemotherapy p
No. (%) Yes (n = 24) No (n = 31)
Sex
 Male 42 (76%) 18 (75%) 24 (77%) 1
 Female 13 (23%) 6 (25%) 7 (23%)
Age (years) (Median, Range) 66 (38–82) 66 (38–82) 68 (49–80) 0.48
ECOG performance status
 0 8 (14%) 8 (33%) 0 (0%) < 0.001
  ≥ 1 47 (86%) 16 (67%) 31 (100%)
Disease status
 Metastatic 41 (74%) 18 (75%) 23 (74%) 1
 Relapsed 14 (26%) 6 (25%) 8 (26%)
Primary site
 Gastric 48 (87%) 22 (92%) 26 (84%) 0.451
 Esophagogastric junction 7 (13%) 2 (8%) 5 (16%)
Histological type
 Intestinal type 31 (56%) 12 (50%) 19 (61%) 0.426
 Diffuse type 24 (44%) 12 (50%) 12 (39%)
HER-2 status
 Positive 13 (24%) 3 (12%) 10 (32%) 0.116
Site of metastases
 Lymph nodes 38 (69%) 15 (62%) 23 (74%) 0.391
 Hematogenous 32 (58%) 11 (46%) 21 (68%) 0.168
 Peritoneum 26 (47%) 12 (50%) 14 (45%) 0.789
Organs with metastasis
 1 16 (29%) 10 (42%) 6 (19%) 0.083
  ≥ 2 39 (71%) 14 (58%) 25 (81%)
Previous treatment regimens
 2 34 (62%) 17 (71%) 17 (55%) 0.459
 3 16 (29) 5 (21%) 11 (35%)
  ≥ 4 5 (9%) 2 (8%) 3 (10%)
Previous therapies
 Pyrimidine analogs 53 (96%) 23 (96%) 30 (97%) 1
 Platinum 47 (86%) 20 (83%) 27 (87%) 0.718
 Taxane 52 (94%) 23 (96%) 29 (94%) 1
 Ramucirumab 46 (84%) 20 (83%) 26 (84%) 0.471
 Trastuzumab 11 (20%) 1 (4%) 10 (32%) 0.015
 Irinotecan 14 (26%) 5 (21%) 9 (29%) 0.547
Treatment period before nivolumab (months) 14.9 (4.9–64.6) 14.5 (5.8–64.6) 15.0 (4.9–45.8) 0.819
Best overall response
 Responder 18 (33%) 12 (50%) 6 (19%) 0.022
 Non-responder 37 (67%)) 12 (50%) 25 (81%)
Immune-related adverse events (≥grade 2)
 Positive 18 (33%) 9 (38%) 9 (29%) 0.57